Drug Design, Development and Therapy
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Risk factors in patients with AFB smear-positive sputum who receive inappropriate antituberculous treatment
(4066) Total Article Views
Authors: Chang CY, Hong JY, Yuan MK, Chang SJ, Lee YM, Chang SC, Hsu LC, Cheng SL
Published Date January 2013
Volume 2013:7 Pages 53 - 58
|Received:||16 October 2012|
|Accepted:||21 November 2012|
|Published:||31 January 2013|
1Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan; 2Department of Internal Medicine, 3Department of Radiology, 4Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; 5Department of Industrial Management and Enterprise Information, Aletheia University, Taipei, Taiwan; 6Department of Laboratory Medicine, National Yang-Ming University Hospital, Yilan, Taiwan
*These authors contributed equally to this work
Background: Acid-fast bacilli (AFB) smear-positive sputum is usually an initial clue in the diagnosis of pulmonary tuberculosis (TB); however, the test is not disease-specific. Nontuberculous mycobacterium-related colonization or lung disease often has AFB smear-positive sputum results, and physicians may prescribe unnecessary antituberculous drugs for these patients. The aim of this study was to analyze the clinical characteristics of patients with AFB smear-positive sputum who received unnecessary anti-TB treatment.
Methods and patients: From January 2008 to July 2011, we retrospectively enrolled 97 patients with AFB smear-positive sputum who did not have pulmonary TB according to mycobacterial cultures and clinical judgment. We analyzed the clinical and radiographic features of the patients who received inappropriate and unnecessary anti-TB treatment. Preliminary analyses of chi-square and Fisher's exact tests were applied to determine factors unlikely to be associated with the independent variables. The relationship between independent covariates was then analyzed using multivariate logistic regression.
Results: Of the 97 enrolled patients, 25 (25.8%) were diagnosed with pulmonary TB and prescribed anti-TB drugs (mostly a combination of isoniazid, rifampicin, ethambutol, and pyrazinamide). The other 72 (74.2%) patients were not initially diagnosed with pulmonary TB and were classified as the control group. Compared to the control group, the patients who received inappropriate anti-TB treatment had more chronic cough as presentation symptom and heavy AFB Ziehl–Neelsen staining in sputum (>10/100 fields, grading 2+ to 4+). There were no significant differences in the radiographic analysis between the two groups.
Conclusion: Among the patients with AFB smear-positive sputum that did not have pulmonary TB, chronic cough and heavy AFB staining (2+ to 4+) were risk factors for the inappropriate administration of unnecessary anti-TB treatment.
Keywords: AFB smear-positive sputum, Mycobacterium tuberculosis, antituberculous treatment
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- MLA'14 -
May 16–21, 2014
- ISPOR International meeting
May 31 - June 4, 2014
- CINP World Congress
22 - 26 June, 2014
- Cancer Pharmacogenomics and Targeted Therapies
17 - 19 September, 2014
- ESMO 2014 Congress
26 - 30 September, 2014
- 27th ECNP Congress
18 - 21 October, 2014
- ISPOR 17th Annual European Congress 2014
8 - 12 November, 2014
Amsterdam, The Netherlands
- Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
- The benefits and risks of testosterone replacement therapy: a review
- Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
- Tenofovir-associated bone density loss